OGN

TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Women's Health Collective Canada (WHCC) and the Partnership for Women's Health Research Canada (PWHR), in partnership with GreenShield and supported by a charitable grant from Organon, have launched the Researching Information, Support, and Equity During the Menopause Transition in Canada (Can-RISE) Study. As the first national investigator-led study focused on Canadian women's experiences of menopause and the menopausal transition, Can-RISE is led by PWHR with funding support from WHCC.

Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Organon (OGN) came out with quarterly earnings of $0.85 per share, missing the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $1 per share a year ago.

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the company's Board of Directors declared a quarterly dividend of $0.02 for each issued and outstanding share of the company's common stock. The dividend is payable on September 10, 2026, to stockholders of record at the close of business on August 14, 2026. About Organon Organon (NYSE: OGN) is a global h.

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Presents VTAMA (tapinarof) cream, 1% Analysis of Phase3 Pooled Data Showing Early Consistent Improvements in Eczema Patients Across Age Groups.

Shareholders of Organon & Co. NYSE: OGN approved the company's proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting held Wednesday, according to preliminary voting results announced during the meeting.

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its second quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission (“SEC”). The company also plans to disclose certain non-GAAP financial measures and their reconciliation to their comparable GAAP measures for the second quarter 2026, which will.

Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.